Health & Wellness Blog - Page 80

GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection

A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.

Shotlee·Feb 14, 2026·7 min read

Peptide Therapy

Semax: Potential of a Synthetic Peptide in Neuroscience Research

Semax, a synthetic heptapeptide derived from ACTH research, is capturing interest for its neuroactive properties without endocrine effects. Ongoing studies highlight its roles in neuroplasticity, stress resilience, and cognitive function. This guide delves into the science behind its multifaceted research potential.

Shotlee·Feb 14, 2026·5 min read

Obesity Treatment

How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned

GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.

Shotlee·Feb 14, 2026·5 min read

GLP-1 Medications

GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk

Emerging research is spotlighting a potential link between popular GLP-1 medications like Ozempic and Wegovy and hair loss conditions such as telogen effluvium and androgenetic alopecia. A study of nearly 550,000 patients found a significant association after 12 months of use, even after adjusting for key factors. While benefits for diabetes and weight loss remain strong, awareness and monitoring are crucial.

Shotlee·Feb 14, 2026·6 min read

GLP-1 Medications

Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal

Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.

Shotlee·Feb 13, 2026·5 min read

GLP-1 Medications

Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says

Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.

Shotlee·Feb 13, 2026·5 min read

GLP-1 Side Effects

Bunnie Xo Reveals 'Horrific' Suicidal Ideation from GLP-1 Medication

Jelly Roll's wife, Bunnie Xo, described a 'horrific' bout of suicidal ideation as a side effect from taking a GLP-1 medication last year. The Dumb Blonde podcast host opened up to PEOPLE about this dark period, emphasizing the need for open conversations on GLP-1 side effects. Despite family diabetes history prompting her use, she urges others: 'Please stay.'

Shotlee·Feb 13, 2026·6 min read

GLP-1 Medications

Pricey GLP-1 Drugs Raising Insurance Premiums for Everyone, Expert Says

The surge in GLP-1 drug use, with 12% of U.S. adults already on them, is costing more than just patients—their high prices are fueling 30% of recent health insurance premium hikes, says Harvard's Luca Maini. While effective for weight loss, these blockbuster meds face patent protections and coverage hurdles. Discover the full economic ripple effects and what's ahead.

Shotlee·Feb 13, 2026·8 min read

GLP-1 Medications

Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod

Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.

Shotlee·Feb 13, 2026·5 min read

Latest Articles

Latest Articles

GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection

Semax: Potential of a Synthetic Peptide in Neuroscience Research

How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned

GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk

Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal

Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says

Bunnie Xo Reveals 'Horrific' Suicidal Ideation from GLP-1 Medication

Pricey GLP-1 Drugs Raising Insurance Premiums for Everyone, Expert Says

Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod

Latest Articles

GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection

Semax: Potential of a Synthetic Peptide in Neuroscience Research

How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned

GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk

Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal

Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says

Bunnie Xo Reveals 'Horrific' Suicidal Ideation from GLP-1 Medication

Pricey GLP-1 Drugs Raising Insurance Premiums for Everyone, Expert Says

Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod